The FDA Peptide Vote, Read for Women: 6 of 7 Passed — Here's What Matters
Coverage of the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting has focused on athletes, biohackers, and the recovery-peptide crowd. Fair enough — that's where the loudest social conversation lives. But three of the six peptides the committee recommended have particularly relevant women's-health signals hidden inside their evaluated indications, and one of the rejections closes a door that had been quietly open for perimenopausal sleep protocols. Here is the meeting read specifically for women.
The Meeting in One Table
| Peptide | Vote | Evaluated For | Female-Skew Relevance |
|---|---|---|---|
| BPC-157 | 8–6, 1 abstain | Ulcerative colitis | IBD occurs ~1.3x more often in women |
| KPV | 8–6, 1 abstain | Wound healing, inflammatory conditions | Autoimmune skew (2–3x female) |
| TB-500 | 8–6, 1 abstain | Wound healing | Postpartum tissue recovery research interest |
| MOTS-c | 7–5, 2 abstain | Obesity, osteoporosis | Postmenopausal bone loss |
| Semax | 8–5, 1 abstain* | Cerebral ischemia, migraine | Migraine skews 3x female |
| Epitalon | 7–5, 1 abstain* | Insomnia | Perimenopausal sleep disruption |
| Emideltide (DSIP) | 6–7 — rejected | Insomnia, opioid withdrawal, narcolepsy | Deep-sleep protocols — loses queue position |
*Day 2 tallies as reported from the live webcast, pending official transcript.
Where Female Physiology Actually Intersects the Votes
Autoimmune and inflammatory conditions (KPV, BPC-157)
Autoimmune disease affects women at roughly two to three times the rate it affects men, and inflammatory bowel disease specifically runs slightly female-skewed. Two of the six recommended peptides — KPV and BPC-157 — were evaluated for exactly this territory. If either eventually reaches the 503A list, women will disproportionately be the patient population served. That is not speculation; it is the demographic math of the evaluated indications.
Bone loss (MOTS-c)
MOTS-c was evaluated for osteoporosis alongside obesity. Postmenopausal bone density loss is one of the largest under-treated women's health issues in the developed world, and the current pharmacological toolkit — bisphosphonates, denosumab, teriparatide — has significant limitations. A mitochondrial-derived peptide with metabolic and skeletal effects entering the compounding pipeline is a specifically female-relevant development, even if it is years from the shelf.
Migraine (Semax)
The FDA evaluated Semax for cerebral ischemia, migraine, and trigeminal neuralgia. Migraine prevalence in women is roughly three times higher than in men, and the perimenopausal transition is a peak migraine window. Prescription-strength Semax is not a serious near-term treatment option — the road runs 12 to 24 months of rulemaking if it runs at all — but the indication itself is heavily female.
Perimenopausal sleep (Epitalon in; DSIP out)
Epitalon quietly cleared the panel with insomnia as the FDA-evaluated indication — not the anti-aging or telomere claims it is famous for online. DSIP was rejected, and one of its evaluated uses was chronic insomnia. Perimenopausal sleep disruption is one of the most common midlife women's-health complaints, so the winner-and-loser split here matters more for women than the coverage has acknowledged.
What Did Not Change (Important)
None of these votes made anything legal. A PCAC recommendation is advice to the FDA. Formal rulemaking — the process of actually adding a substance to the 503A list — typically takes 12 to 24 months when the agency proceeds, and glutathione (recommended by this same committee in 2022) is still uncodified four years later. Nothing changes at your compounding pharmacy today.
The Bigger Picture for Women's Peptide Research
Two things are true at once. First, this meeting was the most favorable regulatory signal peptides have received in years — the direction of travel is genuinely toward more legal access, not less. Second, the FDA's own scientists opposed all seven recommendations, and the committee majorities were narrow every time. That means the evidence base is contested rather than settled, and it means women considering these compounds today are still working with the same thin research base they were in June. If you want prescribed, physician-supervised care through what is already legal, Veritide independently ranks licensed telehealth providers including several with women's health focus.
For specific compound follow-ups: our KPV autoimmune piece, the perimenopause sleep breakdown, and the MOTS-c bone-density read all go deeper.
Third-party tested research peptides with published COAs. Code POWER at checkout.
Code: POWERView Catalog →US-based research supplier, batch-tested catalog. Code POWER at checkout.
Code: POWERView Catalog →Reader-supported links. We may earn a commission at no cost to you. All research compounds are for laboratory use only.
Frequently Asked Questions
Six of seven: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) was the only rejection. All votes were narrow and non-binding.
Several of the evaluated indications are female-skewed - inflammatory bowel disease, autoimmune conditions, osteoporosis, migraine, and perimenopausal insomnia - so the patient populations served, if listings ever happen, would lean female.
No. None of the compounds discussed have adequate pregnancy or lactation safety data, and peptide use is not appropriate during pregnancy or breastfeeding regardless of regulatory status.
None of the seven can be legally compounded until the FDA completes formal rulemaking. That process typically takes 12 to 24 months and may not happen at all.
DSIP, which was rejected 6-7. It had been under review for chronic insomnia, an area where perimenopausal women are disproportionately affected. The failed vote removes it from the near-term legalization queue.